WO2025037336 - PHARMACEUTICAL FORMULATIONS OF ANTI-CD 20 ANTIBODY AND METHODS OF PREPARING THE SAME
National phase entry is expected:
Publication Number
WO/2025/037336
Publication Date
20.02.2025
International Application No.
PCT/IN2024/051485
International Filing Date
11.08.2024
Title **
[English]
PHARMACEUTICAL FORMULATIONS OF ANTI-CD 20 ANTIBODY AND METHODS OF PREPARING THE SAME
[French]
FORMULATIONS PHARMACEUTIQUES D'ANTICORPS ANTI-CD 20 ET LEURS PROCÉDÉS DE PRÉPARATION
Applicants **
DR. REDDY'S LABORATORIES LIMITED
Inventors
JAYARAMAN, Murali
DEOGAM, Anshu
SONI, Siddharth
MARIKANTY, Ravi Kumar
RAJARAMAN, Sucheta
SIGIREDDI, Indra Kumar
LABALA, Suman
Priority Data
202341054213
12.08.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1955 | |
| EPO | Filing, Examination, Granting | 11624 | |
| Japan | Filing, Examination, Granting | 2016 | |
| South Korea | Filing, Examination, Granting | 1788 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,123
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human CD20 and method for preparing the same. The disclosed formulation composition stabilizes anti-CD20 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).[French]
La présente invention concerne des formulations pharmaceutiques d'anticorps et de fragments de liaison à l'antigène contre CD20 humain et leur procédé de préparation. La composition de formulation divulguée stabilise l'anticorps anti-CD20 de concentrations plus faibles à plus élevées, ce qui la rend appropriée pour différents modes d'administration (sous-cutanée/intraveineuse).